These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1969 related articles for article (PubMed ID: 22339463)

  • 1. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads.
    Panza F; Frisardi V; Imbimbo BP; Seripa D; Solfrizzi V; Pilotto A
    Expert Opin Biol Ther; 2011 Jun; 11(6):679-86. PubMed ID: 21501112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.
    Panza F; Frisardi V; Imbimbo BP; D'Onofrio G; Pietrarossa G; Seripa D; Pilotto A; Solfrizzi V
    Immunotherapy; 2010 Nov; 2(6):767-82. PubMed ID: 21091109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
    Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
    Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Aβ immunotherapy for Alzheimer's disease].
    Sakai K; Yamada M
    Brain Nerve; 2013 Apr; 65(4):461-8. PubMed ID: 23568994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab.
    Panza F; Frisardi V; Imbimbo BP; Seripa D; Paris F; Santamato A; D'Onofrio G; Logroscino G; Pilotto A; Solfrizzi V
    Curr Alzheimer Res; 2011 Dec; 8(8):808-17. PubMed ID: 21592055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.
    Panza F; Solfrizzi V; Imbimbo BP; Tortelli R; Santamato A; Logroscino G
    Expert Rev Clin Immunol; 2014 Mar; 10(3):405-19. PubMed ID: 24490853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid beta peptide immunotherapy in Alzheimer disease.
    Delrieu J; Ousset PJ; Voisin T; Vellas B
    Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.
    Cribbs DH
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):207-16. PubMed ID: 20205639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?
    Li Y; Liu Y; Wang Z; Jiang Y
    Expert Opin Biol Ther; 2013 Nov; 13(11):1515-22. PubMed ID: 24053611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solanezumab for the treatment of mild-to-moderate Alzheimer's disease.
    Imbimbo BP; Ottonello S; Frisardi V; Solfrizzi V; Greco A; Seripa D; Pilotto A; Panza F
    Expert Rev Clin Immunol; 2012 Feb; 8(2):135-49. PubMed ID: 22288451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.
    Geylis V; Steinitz M
    Autoimmun Rev; 2006 Jan; 5(1):33-9. PubMed ID: 16338209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of antibody-based therapies to treat Alzheimer's disease: just a matter of timing?
    Cedernaes J; Schiöth HB; Benedict C
    Exp Gerontol; 2014 Sep; 57():104-6. PubMed ID: 24835192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
    Panza F; Solfrizzi V; Imbimbo BP; Logroscino G
    Expert Opin Biol Ther; 2014 Oct; 14(10):1465-76. PubMed ID: 24981190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.
    Lemere CA
    Prog Brain Res; 2009; 175():83-93. PubMed ID: 19660650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solanezumab for Alzheimer's disease.
    Samadi H; Sultzer D
    Expert Opin Biol Ther; 2011 Jun; 11(6):787-98. PubMed ID: 21504387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?
    Tayeb HO; Murray ED; Price BH; Tarazi FI
    Expert Opin Biol Ther; 2013 Jul; 13(7):1075-84. PubMed ID: 23574434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.
    Blennow K; Zetterberg H; Rinne JO; Salloway S; Wei J; Black R; Grundman M; Liu E;
    Arch Neurol; 2012 Aug; 69(8):1002-10. PubMed ID: 22473769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 99.